Medical News

[ Pivotal Data For The Investigational Treatment PSD502 For Primary Premature Ejaculation ]

Pivotal Data For The Investigational Treatment PSD502 For Primary Premature Ejaculation

Shionogi Pharma, Inc., a U.S.-based group company of Shionogi & Co., Ltd., presented data summarizing the results of two pivotal studies of the investigational new drug PSD502, a topical metered dose spray being developed for the treatment of primary premature ejaculation (PE). These data were presented at the 2010 American Urological Association (AUA) Annual Meeting in San Francisco. Evaluating a combined total of 556 (randomized) and 536 (treated) men with primary PE in the United States, Canada and Europe over a three-month period, with more than 23, 000 exposures to PSD502 recorded, the data demonstrated that men who were treated with PSD502 five minutes before intercourse by applying PSD502 via a topical metered dose spray had a time to ejaculation 5.5 times longer than those who used a placebo spray with the actual average measurement in minutes for drug and placebo.

Counterfeit ED Drugs Pose Fatal Health Risks

Counterfeit drugs for erectile dysfunction (ED) can contain toxic materials, too much active ingredient or no active ingredient at all and pose serious health risks, according to research presented at the 105th Annual Scientific Meeting of the American Urological Association (AUA). Taking ED medication that is not prescribed is already dangerous because these medications can interact with other drugs or may not be safe for people with other health conditions, like high blood pressure or cardiovascular disease. Researchers from Korea compared 19 counterfeit drugs to their prescription counterparts and found that the counterfeits not only looked different in size (32 percent) and color (42 percent) but also contained different amounts of the active ingredient. More than half of the tablets (58 percent) contained an excess of active ingredient-more than double the amount for some counterfeits.

Pivotal Data For The Investigational Treatment PSD502 For Primary Premature Ejaculation In The U.S. To Be Presented At Meeting

Shionogi Pharma, Inc., a U.S.-based group company of Shionogi & Co., Ltd., presented data summarizing the results of two pivotal studies of the investigational new drug PSD502, a topical metered dose spray being developed for the treatment of primary premature ejaculation (PE). These data were presented at the 2010 American Urological Association (AUA) Annual Meeting in San Francisco. Evaluating a combined total of 556 (randomized) and 536 (treated) men with primary PE in the United States, Canada and Europe over a three-month period, with more than 23, 000 exposures to PSD502 recorded, the data demonstrated that men who were treated with PSD502 five minutes before intercourse by applying PSD502 via a topical metered dose spray had a time to ejaculation 5.5 times longer than those who used a placebo spray with the actual average measurement in minutes for drug and placebo.

Link Established Between Erectile Dysfunction And Calcified Coronary Arteries

In the largest study to date evaluating erectile dysfunction (ED) and coronary artery calcification, researchers at Mount Sinai School of Medicine have determined that men with ED are at a significantly increased risk of high coronary artery calcification scores (CACS), a known predictor of future cardiovascular events. The research was presented this week at the American Urological Association (AUA) meeting in San Francisco. The study, titled "Erectile Dysfunction is an Independent Risk Factor for the Presence of High Risk Coronary Artery Calcification, " evaluated 1, 119 men enrolled in the World Trade Center Medical Monitoring and Treatment Program, 327 of which had ED. The researchers learned that after adjusting for comorbidities men with ED had a 54 percent greater likelihood of having a high-risk CACS than men without ED.

Fenugreek Not Just For Your Curry; Improves Male Libido Too

Fenugreek for sexual enhancement? Yes. A new study from down under in Australia represents the power of the curry spice to improve male libido and also is key in increasing milk supplies in mothers with newborns. The research, performed by the Centre for Integrative Clinical and Molecular Medicine, showed that men who took a fenugreek extract twice daily saw significant improvements in their love life. The study looked at the effects of a fenugreek-based preparation on the libido of men aged 25 to 52. The men took the extract twice a day for six weeks, while another group had a placebo pill. Within six weeks of starting the trial, men who took the fenugreek had increases in their libido scores of more than 25%. It is still not known how it works, but it certainly does. Fenugreek does contain some compounds that may affect hormone levels.

Fast: [10]

Medical News © Nanda
Designer Damodar